![The Economics of “Delinking” PBM Compensation](https://getmga.com/wp-content/uploads/2023/11/iStock-878855074-e1698884939416-1080x675.jpg)
The Economics of “Delinking” PBM Compensation
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.